Filing Flows › Milestone Pharmaceuticals (MIST) › Q1 2026
Milestone Pharmaceuticals (MIST) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Milestone Pharmaceuticals (MIST) reported revenue of $238K for the first quarter 2026 (Q1 2026).
Milestone Pharmaceuticals, Q1 2026: revenue $238K, net loss $26.1M, operating cash flow −$16.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $238K | — | — |
| Operating profit | −$23.7M | — | — |
| Net earnings | −$26.1M | — | — |
| Operating cash flow | −$16.1M | — | — |
What changed
Revenue was $238K in Q1 2026.
Operating costs exceeded revenue by $23.7M, an operating margin of -9942.4%. The quarter ended with a net loss of $26.1M.
Operating cash flow was −$16.1M. Non-cash charges added back $56K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $8.7M. Capital expenditures of $45K exceeded it, leaving free cash flow of −$16.1M.
Questions
What was Milestone Pharmaceuticals' revenue in the first quarter 2026?
Milestone Pharmaceuticals (MIST) reported revenue of $238K for the first quarter 2026 (Q1 2026).